Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009562 | 1.00 | RNPEP (0.42) | RNPEPFOLH1LMNAMMP1MMP2 | |
| SCHEMBL14906336 | 0.80 | GPR84 (0.45) | — | |
| SCHEMBL6010151 | 0.78 | OR51E2 (0.39) | LMNAMMP1MMP13 | |
| SCHEMBL6010163 | 0.78 | OR51E2 (0.39) | LMNAMMP1MMP13 | |
| SCHEMBL6009481 | 0.77 | TET2 (0.42) | FOLH1 | |
| SCHEMBL6009490 | 0.77 | TET2 (0.42) | FOLH1 | |
| SCHEMBL8714482 | 0.77 | RNPEP (0.48) | RNPEPFOLH1LMNA | |
| SCHEMBL6009564 | 0.76 | RNPEP (0.39) | RNPEPFOLH1 | |
| SCHEMBL6928240 | 0.75 | GPR84 (0.49) | LMNA | |
| SCHEMBL6009873 | 0.75 | CPB2 (0.38) | RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | RNPEP 2950/4885FOLH1 1267/4885LMNA 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.